Copyright
©The Author(s) 2022.
World J Gastrointest Oncol. Jan 15, 2022; 14(1): 75-89
Published online Jan 15, 2022. doi: 10.4251/wjgo.v14.i1.75
Published online Jan 15, 2022. doi: 10.4251/wjgo.v14.i1.75
Figure 2 Schematic of the mechanism of the action of Bromodomain and extra-terminal inhibitors.
Upon Bromodomain and extra-terminal (BET) inhibitors binding to Bromodomains, BET proteins are displaced from chromatin. Lacking domains directly interacting with chromatin, BET proteins fail to activate oncogenes, and thus BET inhibitors exert cytotoxic effects on cancer cells. BET: Bromodomain and extra-terminal.
- Citation: Sun HY, Du ST, Li YY, Deng GT, Zeng FR. Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers. World J Gastrointest Oncol 2022; 14(1): 75-89
- URL: https://www.wjgnet.com/1948-5204/full/v14/i1/75.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i1.75